Ionis hit by safety concerns, rivals Alnylam benefitBiotech insists drug for rare inherited disorder is still approvable. Share XIonis hit by safety concerns, rivals Alnylam benefithttps://pharmaphorum.com/news/ionis-inotersen-meets-efficacy-targets-fap-safety-concerns-spook-investors/
AZ confirms move to acquire cancer specialist AcertaAcerta brings with it a promising lead candidate Share XAZ confirms move to acquire cancer specialist Acertahttps://pharmaphorum.com/news/az-confirms-move-to-acquire-cancer-specialist-acerta/